Yuan Zhao

发表

Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.

L. Luo, C. Fu, Xu Wang, 2018, European journal of medicinal chemistry.

Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.

Yingchao Duan, Yuanyuan Guan, Shao-Jie Zhang, 2022, European journal of medicinal chemistry.

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

J. Ji, Xiaoxiao Hu, S. Cheung, 2015, Molecular Cancer Therapeutics.

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

X. Liu, Xiaomin Song, Zhirong Shen, 2020, Neoplasia.

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.

Zhiwei Wang, X. Liu, L. Luo, 2020, Journal of medicinal chemistry.

Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases.

Yuehua Wu, X. Liu, Shuaishuai Chen, 2023, Journal of medicinal chemistry.

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

N. Rosen, Paul D. Smith, Xiaoxiao Hu, 2020, Molecular oncology.

ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming

Xiao-Yu Zhang, Anwen Ren, Tong-Cun Zhang, 2023, Acta Pharmacologica Sinica.

Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.

Zhiwei Wang, X. Liu, L. Luo, 2020, Journal of medicinal chemistry.